Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.620
+0.070 (4.52%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care.

The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.

Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis.

The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism.

In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome.

The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd.
Entera Bio logo
Country Israel
Founded 2010
IPO Date Jun 28, 2018
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Miranda Toledano

Contact Details

Address:
Kiryat Hadassah Minrav Building, Fifth Floor
Jerusalem, 9112002
Israel
Phone 972 2 532 7151
Website enterabio.com

Stock Details

Ticker Symbol ENTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001638097
CUSIP Number M40527109
ISIN Number IL0011429839
SIC Code 2836

Key Executives

Name Position
Miranda J. Toledano M.B.A. Chief Executive Officer and Director
Dana Yaacov-Garbeli CPA Chief Financial Officer
Dr. Hillel Galitzer M.B.A., Ph.D. Chief Operating Officer
Dr. Gregory Burshtein Ph.D. Chief of Research and Development

Latest SEC Filings

Date Type Title
Nov 20, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 10-Q Quarterly Report
Nov 8, 2024 8-K Current Report
Aug 20, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 9, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 9, 2024 10-Q Quarterly Report
Aug 9, 2024 8-K Current Report
Aug 2, 2024 8-K Current Report
Jun 20, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 20, 2024 ARS Filing